Literature DB >> 15700312

Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment.

Mikiko Asai-Sato1, Yoji Nagashima, Etsuko Miyagi, Ken Sato, Ichiro Ohta, Barbara K Vonderhaar, Fumiki Hirahara.   

Abstract

Prolactin, a peptide hormone essential for the development and function of reproductive organs, is involved in development of breast, prostate and colorectal cancers. However, the role of prolactin on the carcinogenesis of ovarian carcinomas is unclear. In this study, we show that mRNA of prolactin receptor is expressed in 5 out of 9 ovarian carcinoma cell lines, 15 out of 17 cases of surgical samples and all of normal ovarian surface epithelium, while prolactin transcript is detected only in 1 ovarian carcinoma cell line and in 1 of the surgical samples. For the prolactin receptor-positive ovarian carcinoma cells, exogenous prolactin did not affect the proliferation but markedly inhibited apoptosis. Therefore, actual cell growth was enhanced by prolactin in a dose-dependent manner. The blocking of prolactin receptor by antibody severely impaired the antiapoptotic and growth-promoting effects of prolactin. Interestingly, the cisplatin-induced cell death of the prolactin receptor-positive cells was significantly inhibited by pretreatment with prolactin. These findings indicate a responsiveness of ovarian carcinomas to prolactin and suggest that the prolactin/prolactin receptor system may be a new therapeutic target of ovarian carcinomas. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15700312     DOI: 10.1002/ijc.20810

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase.

Authors:  Elizabeth W LaPensee; Sandy J Schwemberger; Christopher R LaPensee; El Mustapha Bahassi; Scott E Afton; Nira Ben-Jonathan
Journal:  Carcinogenesis       Date:  2009-05-14       Impact factor: 4.944

2.  Prolactin prevents chronic stress-induced decrease of adult hippocampal neurogenesis and promotes neuronal fate.

Authors:  Luz Torner; Sandra Karg; Annegret Blume; Mahesh Kandasamy; Hans-Georg Kuhn; Jürgen Winkler; Ludwig Aigner; Inga D Neumann
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

3.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

4.  Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.

Authors:  Prasad Dandawate; Gaurav Kaushik; Chandrayee Ghosh; David Standing; Afreen Asif Ali Sayed; Sonali Choudhury; Dharmalingam Subramaniam; Ann Manzardo; Tuhina Banerjee; Santimukul Santra; Prabhu Ramamoorthy; Merlin Butler; Subhash B Padhye; Joaquina Baranda; Anup Kasi; Weijing Sun; Ossama Tawfik; Domenico Coppola; Mokenge Malafa; Shahid Umar; Michael J Soares; Subhrajit Saha; Scott J Weir; Animesh Dhar; Roy A Jensen; Sufi Mary Thomas; Shrikant Anant
Journal:  Gastroenterology       Date:  2019-11-29       Impact factor: 22.682

5.  Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer.

Authors:  Jongyun Hwang; Sunghun Na; Hyangah Lee; Dongheon Lee
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

6.  Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Authors:  Yunfei Wen; Behrouz Zand; Bulent Ozpolat; Miroslaw J Szczepanski; Chunhua Lu; Erkan Yuca; Amy R Carroll; Neslihan Alpay; Chandra Bartholomeusz; Ibrahim Tekedereli; Yu Kang; Rajesha Rupaimoole; Chad V Pecot; Heather J Dalton; Anadulce Hernandez; Anna Lokshin; Susan K Lutgendorf; Jinsong Liu; Walter N Hittelman; Wen Y Chen; Gabriel Lopez-Berestein; Marta Szajnik; Naoto T Ueno; Robert L Coleman; Anil K Sood
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

7.  Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.

Authors:  Leticia Oliveira-Ferrer; Jasmin Wellbrock; Udo Bartsch; Eva Maria Murga Penas; Jessica Hauschild; Marianne Klokow; Carsten Bokemeyer; Walter Fiedler; Gunter Schuch
Journal:  Mol Cancer       Date:  2013-11-20       Impact factor: 27.401

8.  Expression of prolactin receptor and prolactin in normal and malignant thyroid: a tissue microarray study.

Authors:  Patrícia Costa; Ana Luísa Catarino; Fernanda Silva; Luís G Sobrinho; Maria João Bugalho
Journal:  Endocr Pathol       Date:  2006       Impact factor: 4.056

9.  Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.

Authors:  Sacha J Howell; Elizabeth Anderson; Tom Hunter; Gillian Farnie; Robert B Clarke
Journal:  Breast Cancer Res       Date:  2008-08-05       Impact factor: 6.466

10.  Prolactin and its receptor as therapeutic targets in glioblastoma multiforme.

Authors:  Antonela Sofía Asad; Alejandro Javier Nicola Candia; Nazareno Gonzalez; Camila Florencia Zuccato; Araceli Abt; Santiago Jordi Orrillo; Yael Lastra; Emilio De Simone; Florence Boutillon; Vincent Goffin; Adriana Seilicovich; Daniel Alberto Pisera; María Jimena Ferraris; Marianela Candolfi
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.